glp-1 payment plan The Medicare Bridge program launched July 1, 2026 and gives eligible patients access to GLP-1 drugs for $50/month 🤯, but have you successfully used it yet?! Clinicians and patients are finding The Bridge to Nowhere: Medicare's

In the kidneys, GLP-1RAs lower urea, creatinine, and pro-inflammatory cytokines via AMPK-dependent pathways, supporting renal function during sepsis-induced acute kidney injury

In the United States, FDA approved four-dose Mounjaro and Zepbound KwikPens on January 20, 2026, while single-dose Mounjaro and Zepbound pens and vials also remain in use

Neurorestorative therapies should therefore be evaluated not only by engraftment or lesion volume but also by their ability to restore metabolic homeostasis across the NVU (Fig

gayathri and diksha are very professional, friendly and is constantly taking care of their patients